2022 ESC – Data From REDUCE-IT Trial
Dr. Michael Miller, MD, FACC, FAHA, Chief of Medicine at the Corporal Michael J. Crescenz VA Medical Center in Philadelphia discusses new data from the REDUCE-IT study, which were presented at a late-breaking scientific session at the European Society of Cardiology (ESC) congress, on VASCEPA ®/VAZKEPA ® (icosapent ethyl) in patients with cardiovascular disease and in another study, with patients who smoke.
Michael Miller, MD, FACC, FAHA is Professor of Cardiovascular Medicine, Epidemiology & Public Health at the University of Maryland School of Medicine in Baltimore, MD. His major research interests are disorders of lipid and lipoprotein metabolism, molecular studies of HDL cholesterol, triglycerides and the postprandial response to dietary fat, nontraditional coronary risk factors and clinical
